Genetic and phenotypic profiling of single living circulating tumor cells from patients with microfluidics

Authors:

Abstract
Accurate prediction of the efficacy of immunotherapy for cancer patients through the characterization of both genetic and phenotypic heterogeneity in individual patient cells holds great promise in informing targeted treatments, and ultimately in improving care pathways and clinical outcomes. Here, we describe the nanoplatform for interrogating living cell host-gene and (micro-)environment (NICHE) relationships, that integrates micro- and nanofluidics to enable highly efficient capture of circulating tumor cells (CTCs) from blood samples. The platform uses a unique nanopore-enhanced electrodelivery system that efficiently and rapidly integrates stable multichannel fluorescence probes into living CTCs for in situ quantification of target gene expression, while on-chip coculturing of CTCs with immune cells allows for the real-time correlative quantification of their phenotypic heterogeneities in response to immune checkpoint inhibitors (ICI). The NICHE microfluidic device provides a unique ability to perform both gene expression and phenotypic analysis on the same single cells in situ, allowing us to generate a predictive index for screening patients who could benefit from ICI. This index, which simultaneously integrates the heterogeneity of single cellular responses for both gene expression and phenotype, was validated by clinically tracing 80 non–small cell lung cancer patients, demonstrating significantly higher AUC (area under the curve) (0.906) than current clinical reference for immunotherapy prediction.
Funding Information
  • MOST | National Key Research and Development Program of China (2022YFB3205600)
  • MOST | National Key Research and Development Program of China (2021YFC2302100)
  • 北京市科学技术委员会 | Natural Science Foundation of Beijing Municipality (7212204)
  • MOST | National Natural Science Foundation of China (32071407)
  • MOST | National Natural Science Foundation of China (62003023)
  • MOE | Fundamental Research Funds for the Central Universities (JKF-YG-22-B001)
  • Science foundation of Beijing University Cancer Hospital 2022-5 (A002476)

This publication has 50 references indexed in Scilit: